Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPL-760 in B-cell non-Hodgkin lymphoma, sponsored by HUTCHMED. Primary endpoints: Dose Limiting Toxicities at 28 days and Safety and Tolerability. Started Jan 2022; status: completed.
02
Drugs
HMPL-760
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05190068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190068.